九强生物(300406) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥410,178,554.56, representing a 56.75% increase year-over-year, and a total revenue of ¥1,217,992,018.60 for the year-to-date, up 131.13% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥89,552,156.10, a 67.43% increase year-over-year, with a year-to-date net profit of ¥310,733,277.11, up 254.56%[4] - The basic earnings per share for Q3 2021 was ¥0.15, reflecting a 50.00% increase year-over-year, while the diluted earnings per share also stood at ¥0.15[4] - Total operating revenue for the current period reached ¥1,217,992,018.60, a significant increase of 131.9% compared to ¥526,979,667.47 in the previous period[33] - The total profit for the period was approximately ¥427.48 million, a significant increase from ¥117.25 million in the previous period, representing a growth of 264.5%[36] - The net profit attributable to the parent company was approximately ¥310.73 million, compared to ¥87.64 million in the same period last year, marking an increase of 253.5%[36] - The basic and diluted earnings per share for the current period were both ¥0.53, up from ¥0.17 in the previous period, reflecting a growth of 211.8%[39] Assets and Liabilities - The company's total assets at the end of Q3 2021 amounted to ¥4,789,290,343.14, a 20.83% increase from the end of the previous year[4] - Total assets reached ¥4,789,290,343.14, up 20.8% from ¥3,963,667,036.44 in the previous period[29] - The company's equity attributable to shareholders was ¥3,465,996,202.28, up from ¥3,197,523,553.79 in the previous period, reflecting an increase of 8.4%[29] - Total liabilities increased to ¥1,039,286,471.07, compared to ¥540,198,128.52 in the previous period, marking an increase of 92.5%[29] - The company’s total liabilities increased significantly, with short-term borrowings rising to ¥5,004,350.00, a 43047.16% increase, reflecting new bank loans[7] Cash Flow - The company reported a net cash flow from operating activities of ¥172,353,740.44 for the year-to-date, a significant increase of 756.77%[4] - Cash inflow from operating activities totaled approximately ¥1.05 billion, compared to ¥587.48 million in the previous period, indicating an increase of 78.5%[43] - The net cash flow from operating activities was approximately ¥172.35 million, a substantial increase from ¥20.12 million in the previous period[43] - The net cash flow from financing activities was approximately ¥396.72 million, compared to ¥1.31 billion in the previous period, showing a decrease of 69.7%[46] - The cash and cash equivalents at the end of the period were approximately ¥272.28 million, down from ¥425.81 million at the end of the previous period, indicating a decrease of 36.0%[46] Expenses - Research and development expenses for Q3 2021 were ¥8,751,120.00, a 56.80% increase compared to the same period last year, indicating a focus on enhancing R&D efforts[10] - The company reported a significant increase in long-term receivables, rising to approximately RMB 38.54 million from RMB 20.88 million, an increase of 84.6%[22] - Research and development expenses for the current period were ¥87,511,158.70, compared to ¥55,812,309.30 in the previous period, indicating a rise of 56.8%[33] - The company experienced a 145.97% increase in sales expenses, totaling ¥25,261,440.00, attributed to the acquisition of Mai Xin and increased promotional activities[10] - Total operating costs amounted to ¥787,669,805.66, up 94.3% from ¥405,416,860.49 in the previous period[33] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,864, with the largest shareholder, China Pharmaceutical Investment Co., holding 14.81% of shares[15] - The company has no known related party relationships among its top shareholders, ensuring independent shareholder actions[18] Strategic Developments - The company acquired a 30% stake in Fuzhou Maixin Biotechnology Development Co., increasing its total ownership to 95.55%[19] - The company is optimizing resources in market, channel, R&D, and management for synergistic development post-acquisition[19] - The company plans to issue convertible bonds to unspecified investors, pending regulatory approval[20]